Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer
The KEYMAKER-U03 study is looking at different combinations of immunotherapy [...]
Lenvatinib plus everolimus for patients with metastatic kidney cancer
The treatment of heavily pretreated patients with metastatic kidney cancer [...]
Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment after surgery for [...]
Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer
Further follow-up data from the phase 3 CLEAR study with [...]
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has [...]
